Home » Newsletters » BioWorld Science

BioWorld Science

July 10, 2019

View Archived Issues

New carbapenem antibiotic shows in vitro activity against MDR Gram-negative bacterial infections

Disordered protein domains stay disordered at work

'Minor' subclones, via microenvironment, help cancer spread

Preliminary interim data presented from phase I trials of Celyad's CYAD-01 and CYAD-101

EIP Pharma initiates phase II study of neflamapimod for the treatment of cognitive deficits in HD

Trovagene initiates enrollment in phase Ib/II study of onvansertib in mCRC with KRAS mutation

A novel model for CF-associated airway colonization

Results presented from the international pivotal phase III PLEO-CMT study of PXT-3003

Pivotal phase II data presented for murlentamab in metastatic colorectal adenocarcinoma

Vaxart enters oral universal influenza vaccine collaboration with Janssen

Summit Therapeutics DDS-04 series shows efficacy in sepsis and pneumonia animal models

siRNA targeting hepatitis B virus genes described by Suzhou Ribo Life Science

Phase I/II data presented for BIVV-001 in hemophilia A

Medshine Discovery identifies EGFR/HER2/HER4 inhibitors

New idoleamine 2,3-dioxygenase 1 inhibitors discovered at Hinova Pharmaceuticals

New malaria vaccine successfully tested on Rhesus macaques

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent TLR8 agonists

Merck & Co. identifies new PI3Kdelta inhibitors

'Human-on-a-chip' in vitro system predicts in vivo results for multiple drugs

MET-409 advances into 12-week portion of phase Ib trial in NASH

Cara initiates phase II trial of oral difelikefalin to treat pruritus in atopic dermatitis

PDE4 PET imaging with [11C](R)-rolipram undertaken in patients with McCune-Albright syndrome

Albireo studies elobixibat in phase II for NAFLD and NASH

New gain-of-function mutation in prothrombin is associated with dominant heritable thrombosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...